Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27032770 | 0.83 | FABP5 (0.40) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL29828502 | 0.83 | FABP5 (0.40) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL25657610 | 0.83 | FABP5 (0.40) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL24633713 | 0.83 | KMT2A (0.37) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL25657500 | 0.83 | KMT2A (0.40) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL24633588 | 0.81 | KMT2A (0.36) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL25657611 | 0.80 | KMT2A (0.35) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL25657609 | 0.80 | FABP5 (0.38) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL29633792 | 0.79 | NPSR1 (0.41) | KMT2AFABP5FABP7EPHX2POLB | |
| SCHEMBL22454760 | 0.79 | NPSR1 (0.41) | KMT2AFABP5FABP7EPHX2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.